Search research articles
Contact Us
Filters
Showing results (51-60 of 64) with videos related to
Page
of 7
Sort By:
Preventive Medicine
|
March 1, 1991
Risk factor changes after cessation of intervention in the Multiple Risk Factor Intervention Trial. The MRFIT Research Group
J A Cutler, G A Grandits, R H Grimm, et al.
American Heart Journal
|
October 1, 1986
Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial
W B Kannel, J D Neaton, D Wentworth, et al.
The Medical Journal of Australia
|
March 5, 1990
Differentiation of Becker muscular dystrophy from limb-girdle muscular dystrophy and Kugelberg-Welander disease using a cDNA probe
N G Laing, M E Mears, H E Thomas, et al.
Nucleic Acids Research
|
July 25, 1990
Duchenne muscular dystrophy (DMD) gene cDNA 8 PstI and TaqI polymorphisms involve exon 51 of the HindIII map
N G Laing, P A Akkari, D C Chandler, et al.
Heart (British Cardiac Society)
|
November 4, 2008
Local vessel injury following percutaneous coronary intervention does not promote early mobilisation of endothelial progenitor cells in the absence of myocardial necrosis
H E Thomas, P J Avery, J M Ahmed, et al.
The Medical Journal of Australia
|
January 7, 1991
The diagnosis of Duchenne and Becker muscular dystrophies: two years' experience in a comprehensive carrier screening and prenatal diagnostic laboratory
N G Laing, M E Mears, D C Chandler, et al.
Diabetes
|
November 15, 2000
Virus-induced autoimmune diabetes: most beta-cells die through inflammatory cytokines and not perforin from autoreactive (anti-viral) cytotoxic T-lymphocytes
S Seewaldt, H E Thomas, M Ejrnaes, et al.
American Heart Journal
|
September 1, 1983
Mitral valve prolapse in the general population. 2. Clinical features: the Framingham Study
D D Savage, R B Devereux, R J Garrison, et al.
Trials
|
May 23, 2022
Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)-study protocol for a phase 2, randomized, placebo controlled trial
M Waibel, H E Thomas, J M Wentworth, et al.
Diabetes
|
January 1, 1997
Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice
M B French, J Allison, D S Cram, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 64) with videos related to
Sort By:
Page
of 7
Preventive Medicine
|
March 1, 1991
Risk factor changes after cessation of intervention in the Multiple Risk Factor Intervention Trial. The MRFIT Research Group
J A Cutler, G A Grandits, R H Grimm, et al.
American Heart Journal
|
October 1, 1986
Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial
W B Kannel, J D Neaton, D Wentworth, et al.
The Medical Journal of Australia
|
March 5, 1990
Differentiation of Becker muscular dystrophy from limb-girdle muscular dystrophy and Kugelberg-Welander disease using a cDNA probe
N G Laing, M E Mears, H E Thomas, et al.
Nucleic Acids Research
|
July 25, 1990
Duchenne muscular dystrophy (DMD) gene cDNA 8 PstI and TaqI polymorphisms involve exon 51 of the HindIII map
N G Laing, P A Akkari, D C Chandler, et al.
Heart (British Cardiac Society)
|
November 4, 2008
Local vessel injury following percutaneous coronary intervention does not promote early mobilisation of endothelial progenitor cells in the absence of myocardial necrosis
H E Thomas, P J Avery, J M Ahmed, et al.
The Medical Journal of Australia
|
January 7, 1991
The diagnosis of Duchenne and Becker muscular dystrophies: two years' experience in a comprehensive carrier screening and prenatal diagnostic laboratory
N G Laing, M E Mears, D C Chandler, et al.
Diabetes
|
November 15, 2000
Virus-induced autoimmune diabetes: most beta-cells die through inflammatory cytokines and not perforin from autoreactive (anti-viral) cytotoxic T-lymphocytes
S Seewaldt, H E Thomas, M Ejrnaes, et al.
American Heart Journal
|
September 1, 1983
Mitral valve prolapse in the general population. 2. Clinical features: the Framingham Study
D D Savage, R B Devereux, R J Garrison, et al.
Trials
|
May 23, 2022
Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)-study protocol for a phase 2, randomized, placebo controlled trial
M Waibel, H E Thomas, J M Wentworth, et al.
Diabetes
|
January 1, 1997
Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice
M B French, J Allison, D S Cram, et al.
Page
of 7